Home | Money News | Archives | Contact Us

Search This Site:

Home | Contact Us | News Archives | Resources

Hospira Announces A Nationwide Recall Of One Lot Of Hydromorphone Hydrochloride Injjection

Safety Home Safety Recalls, Market Withdrawals, & Safety Alerts

Section Contents Menu
Recalls, Market Withdrawals, & Safety Alerts

PHOTO – Consumer Alert – Undeclared Sulfites In Dried Dates
PHOTO – Eating Right Soy Protein Burgers Allergy Alert And Voluntary Recall Due to Undeclared Milk
PHOTO – Pacific Oyster Company Issues Allergy Alert On Undeclared Sulfites In Nate’s Spiced Prawns
PHOTO – Rhythm Superfoods Announces Allergy Alert and Voluntary Recall of Kool Ranch Kale Chips
PHOTO – Wells Enterprises Issues Allergy Alert and Voluntary Recall due to Undeclared Wheat in some Blue Bunny Personals Ice Cream
PHOTO – Krasdale Foods Inc. Issues Allergy Alert On Undeclared Almonds In Krasdale Crispy Honey Oats and Flakes
PHOTO – Mars Food US Recalls Two Date Codes of UNCLE BEN’S Whole Grain White Rice Garden Vegetable Due to Undeclared Milk
PHOTO – Rite Aid Voluntarily Recalls 12 oz. Tins of Rich Fields Butter Cookies
Archive for Recalls, Market Withdrawals & Safety Alerts

Enforcement Reports

Industry Guidance

Major Product Recalls

- Recall — Firm Press Release

FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.

Hospira Announces A Nationwide Voluntary Recall Of One Lot Of Hydromorphone Hydrochloride Injection 1 MG/ML, (C-II) 1 ML Fill In 2.5 ML Carpuject, That May Contain More Than The Intended Fill Volume


Hospira Medical Communications

(224) 212-2357

FOR IMMEDIATE RELEASE – May 12, 2012 – Hospira, Inc. (NYSE: HSP), announced today it is initiating a voluntary user level recall of one lot of Hydromorphone Injection, USP, 1 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject™, NDC 0409-1283-31, due to two reported complaints of a single Carpuject containing more than the 1 mL labeled fill volume.

Opioid pain medications such as Hydromorphone have life-threatening consequences if overdosed. Those consequences can include respiratory depression (slowed breathing or suspension of breathing), low blood pressure and reduced heart rate including circulatory collapse.

The affected product is a prefilled glass cartridge for use with the Carpuject Syringe system. The affected lot number is 07547LL. The expiration date is July 1, 2013.

The affected lot was distributed in September – October 2011. It was initially distributed to wholesalers and a limited number of hospitals in Alaska, Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Delaware, Florida, Indiana, Louisiana, Maryland, Massachusetts, Minnesota, Missouri, Mississippi, North Carolina, New Hampshire, New Jersey, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Tennessee, Texas, Utah, Washington, and Wisconsin. Hospira is undertaking this recall in consideration of the potential for safety issues if the product is administered to patients.

Hospira has not received any reports of adverse events related to this issue for this lot. Hospira has initiated an investigation to determine the root cause and preventive actions. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.

Anyone with an existing inventory should stop use and distribution, quarantine the product immediately, and call Stericycle at 1-888-912-7093 to arrange for the return of the product. Replacement product from other lots is available. Customers can send their DEA 222 form to Hospira, 1635 Stone Ridge Drive, Stone Mountain, GA 30083 to order replacement product.

For medical inquiries, please contact Hospira Medical Communications at 1-800-615-0187. This phone number is available 24 hours a day, seven days a week.
Any adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Events Program either online, buy regular mail or by fax.

Online: www.fda.gov/medwatch/report.htm1
Regular mail: use postage-paid, pre-addressed Form FDA3500 available at www.fda.gove/MedWatch/getforms.htm2
Fax: 1-800-FDA-0178

Posted in Government | Tagged | Comments closed
  • RSS Economic Analysis

    • U.S. International Trade in Goods and Services, March 2012
      The U.S. Census Bureau and the U.S. Bureau of Economic Analysis, through the Department of Commerce, announced today that total March exports of $186.8 billion and imports of $238.6 billion resulted in a goods and services deficit of $51.8 billion, up from $45.4 billion in February, revised. March exports were $5.3 billion more than February exports of $181. […]
  • RSS Budget Office

  • RSS Economic Outlook

    • S. 414, International Protecting Girls by Preventing Child Marriage Act of 2011
      As ordered reported by the Senate Committee on Foreign Relations on February 14, 2012 S. 414 would authorize the President to provide assistance to developing countries to reduce the incidence of child marriage and would require him to develop and implement a multiyear strategy to prevent such marriages and promote the empowerment of girls. CBO estimates tha […]
    • H.R. 4310, National Defense Authorization Act for Fiscal Year 2013
      As reported by the House Committee on Armed Services on May 11, 2012 read more […]
    • S. 657, National Blue Alert Act of 2011
      As reported by the Senate Committee on the Judiciary on September 8, 2011 S. 657 would require the Department of Justice (DOJ) to establish a national communications network to issue alerts (that would be known as “blue alerts”) when a law enforcement officer is killed or seriously injured. The bill also would authorize the appropriation of $10 million annua […]
    • H.R. 2446, RESPA Home Warranty Clarification Act of 2011
      As ordered reported by the House Committee on Financial Services on March 27, 2012 read more […]
    • H.R. 4607, Midnight Rule Relief Act of 2012
      As ordered reported by the House Committee on Oversight and Government Reform on April 26, 2012 H.R. 4607 would prohibit federal agencies from promulgating significant regulatory actions from Election Day through Inauguration Day unless an incumbent President is reelected. The bill defines significant regulatory actions as those having an impact of more than […]